Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 2/20 | 0.66 |
| ▸ | HTR2C | P28335 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | CCR3 | P51677 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13503942 | 0.90 | SIGMAR1 (0.64) | HTR2ACYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL7952371 | 0.83 | ACHE (0.66) | ACHEKDM4ECCR3SIGMAR1 | |
| SCHEMBL25531122 | 0.83 | SIGMAR1 (0.61) | ACHEHTR2AHTR2CKDM4ECYP1A2 | |
| SCHEMBL12384539 | 0.81 | SLC6A3 (0.56) | ACHEHTR2AHTR2CKDM4ECYP1A2 | |
| SCHEMBL12424500 | 0.81 | CCR3 (0.73) | ACHEHTR2AHTR2CKDM4ECYP1A2 | |
| SCHEMBL28062553 | 0.81 | HTR2A (0.59) | ACHEHTR2AHTR2CKDM4ECYP1A2 | |
| SCHEMBL25530986 | 0.81 | HTR2A (0.46) | ACHEHTR2AHTR2CKDM4ECYP1A2 | |
| SCHEMBL152736 | 0.81 | ACHE (1.00) | ACHEHTR2AHTR2CKDM4ECYP1A2 | |
| SCHEMBL19728167 | 0.81 | ACHE (0.69) | ACHEKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18673331 | 0.80 | LTA4H (0.57) | KDM4ECYP1A2CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190081-A1 | META SUBSTITUTED PHENYLPYRAZOLO- AND PHENYLPYRROLO- PYRIDAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-06-18 | — | — | US | disclosed |
| US-10035790-B2 | RORγ modulators | EXELIXIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2170860-B9 | BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2017-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035790-B2 | RORγ modulators | RORB, RORA, RORC | ACHE 3334/4885HTR2A 2827/4885HTR2C 3823/4885 |
| US-20200190081-A1 | META SUBSTITUTED PHENYLPYRAZOLO- AND PHENYLPYRROLO- PYRIDAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | TRPV1, TRPV2, CACNG2 | ACHE 384/4885HTR2A 141/4885HTR2C 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.